Hans Biomed Corp
KOSDAQ:042520
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Hans Biomed Corp
Cash from Financing Activities
Hans Biomed Corp
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hans Biomed Corp
KOSDAQ:042520
|
Cash from Financing Activities
₩41.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
8%
|
CAGR 10-Years
43%
|
|
|
Celltrion Inc
KRX:068270
|
Cash from Financing Activities
₩339.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
5%
|
CAGR 10-Years
10%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Cash from Financing Activities
₩123.8B
|
CAGR 3-Years
30%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Cash from Financing Activities
₩3.9B
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Cash from Financing Activities
₩155.6B
|
CAGR 3-Years
276%
|
CAGR 5-Years
15%
|
CAGR 10-Years
103%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Cash from Financing Activities
₩32.5B
|
CAGR 3-Years
91%
|
CAGR 5-Years
122%
|
CAGR 10-Years
N/A
|
|
Hans Biomed Corp
Glance View
Hans Biomed Corp. engages in the manufacture and sale of graft material and silicon products. The company is headquartered in Seoul, Seoul. The company went IPO on 2009-10-09. The firm mainly provides three categories of products: skin-implant materials, bone-implant materials and silicone products. Its skin-implant materials are used for burn treatment and skin graft under the brand names of SureDerm, BellaGen and GPS. Its bone-implant materials include allogeneic bones, xenogenous bones and synthetic bones used in dentistry, orthopedic and others, which are under the brand names of SureFuse, ExFuse and SureOss. Its silicone products are used for treatments of scars and for breast implant and others, which are under the brand names of BellaGel and Scar Clinic. In addition, it provides hair transplanters and others.
See Also
What is Hans Biomed Corp's Cash from Financing Activities?
Cash from Financing Activities
41.7B
KRW
Based on the financial report for Dec 31, 2025, Hans Biomed Corp's Cash from Financing Activities amounts to 41.7B KRW.
What is Hans Biomed Corp's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
43%
Over the last year, the Cash from Financing Activities growth was 615%. The average annual Cash from Financing Activities growth rates for Hans Biomed Corp have been 24% over the past three years , 8% over the past five years , and 43% over the past ten years .
